Pathology & Oncology Research

, Volume 25, Issue 1, pp 115–121 | Cite as

Krüppel-Like Factor 8 Overexpression Correlates with Poor Prognosis in Non-Small Cell Lung Cancer

  • Jianchao Li
  • Yifei Liu
  • Jianhua Xue
  • Mingming Xu
  • Jianguo Zhang
  • Junhua LiuEmail author
  • Wenyi WangEmail author
Original Article


Krüppel-like factor 8 (KLF8) plays a key role in cancer progression. However, its expression pattern and relationship with clinicopathological characteristics in non-small cell lung cancer (NSCLC) has not been completely elucidated. The study aimed to investigate the expression of KLF8 and its correlation with clinical pathologic features in NSCLC and to explore the potential mechanism. The expression of KLF8 in NSCLC was detected by RT-PCR, Western blot and immunohistochemistry. The expression of Vimentin and E-cadherin, epithelial-mesenchymal transition (EMT) markers, were detected by immunohistochemistry in the NSCLC. The relationship between KLF8 expression and various clinicopathological features or EMT markers was investigated. The results showed m-RNA and protein of KLF8 were overexpressed in NSCLC and the percent of KLF8 positive cells was positively correlated with TNM stage, lymph node metastasis and poor overall survive. Moreover, high expression of KLF8 correlated with E-cadherin low expression, and Vimentin overexpression. Additionally, COX multivariate regression analysis suggested that TNM stage, KLF8, E-cadherin and Vimentin were independent prognostic indicators for overall survival of patients with NSCLC. The data demonstrate that KLF8 is overexpressed in NSCLC. KLF8 overexpression promotes the malignancy of NSCLC, which mechanism may be involved in EMT. KLF8 maybe serve as a potential therapeutic target for NSCLC.


Krüppel-like factor 8 Non-small cell lung cancer Pithelial-mesenchymal transition Prognosis 


Compliance with Ethical Standards

Conflict of Interest



  1. 1.
    Jemal A et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90CrossRefGoogle Scholar
  2. 2.
    Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62(1):10–29CrossRefGoogle Scholar
  3. 3.
    Gao W et al (2011) Circulating microRNAs: possible prediction biomarkers for personalized therapy of non-small-cell lung carcinoma. Clin Lung Cancer 12(1):14–17CrossRefGoogle Scholar
  4. 4.
    Smith CB, Kelley AS, Meier DE (2010) Evidence for new standard of care in non-small cell lung cancer patients. Semin Thorac Cardiovasc Surg 22(3):193–194CrossRefGoogle Scholar
  5. 5.
    Pearson R et al (2008) Kruppel-like transcription factors: a functional family. Int J Biochem Cell Biol 40(10):1996–2001CrossRefGoogle Scholar
  6. 6.
    Zhao J et al (2003) Identification of transcription factor KLF8 as a downstream target of focal adhesion kinase in its regulation of cyclin D1 and cell cycle progression. Mol Cell 11(6):1503–1515CrossRefGoogle Scholar
  7. 7.
    Wang X, Zhao J (2007) KLF8 transcription factor participates in oncogenic transformation. Oncogene 26(3):456–461CrossRefGoogle Scholar
  8. 8.
    Quadrini KJ, Bieker JJ (2002) Kruppel-like zinc fingers bind to nuclear import proteins and are required for efficient nuclear localization of erythroid Kruppel-like factor. J Biol Chem 277(35):32243–32252CrossRefGoogle Scholar
  9. 9.
    van Vliet J, Turner J, Crossley M (2000) Human Kruppel-like factor 8: a CACCC-box binding protein that associates with CtBP and represses transcription. Nucleic Acids Res 28(9):1955–1962CrossRefGoogle Scholar
  10. 10.
    Wang X et al (2007) Kruppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion. Cancer Res 67(15):7184–7193CrossRefGoogle Scholar
  11. 11.
    Wang X et al (2008) Activation of KLF8 transcription by focal adhesion kinase in human ovarian epithelial and cancer cells. J Biol Chem 283(20):13934–13942CrossRefGoogle Scholar
  12. 12.
    Wang X et al (2011) KLF8 promotes human breast cancer cell invasion and metastasis by transcriptional activation of MMP9. Oncogene 30(16):1901–1911CrossRefGoogle Scholar
  13. 13.
    Fu WJ et al (2010) Small interference RNA targeting Kruppel-like factor 8 inhibits the renal carcinoma 786-0 cells growth in vitro and in vivo. J Cancer Res Clin Oncol 136(8):1255–1265CrossRefGoogle Scholar
  14. 14.
    Yang T et al (2012) Kruppel-like factor 8 is a new Wnt/beta-catenin signaling target gene and regulator in hepatocellular carcinoma. PLoS One 7(6):e39668CrossRefGoogle Scholar
  15. 15.
    Li JC et al (2010) Up-regulation of Kruppel-like factor 8 promotes tumor invasion and indicates poor prognosis for hepatocellular carcinoma. Gastroenterology 139(6):2146–2157 e12CrossRefGoogle Scholar
  16. 16.
    Liu L et al (2012) Lentivirus-delivered Kruppel-like factor 8 small interfering RNA inhibits gastric cancer cell growth in vitro and in vivo. Tumour Biol 33(1):53–61CrossRefGoogle Scholar
  17. 17.
    Wang WF et al (2013) Kruppel-like factor 8 overexpression is correlated with angiogenesis and poor prognosis in gastric cancer. World J Gastroenterol 19(27):4309–4315CrossRefGoogle Scholar
  18. 18.
    Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454CrossRefGoogle Scholar
  19. 19.
    Iwatsuki M et al (2010) Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 101(2):293–299CrossRefGoogle Scholar
  20. 20.
    Thiery JP et al (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871–890CrossRefGoogle Scholar
  21. 21.
    Goldstraw P (2009) The 7th Edition of TNM in Lung Cancer: what now? J Thorac Oncol 4(6):671–673CrossRefGoogle Scholar
  22. 22.
    Tischler V et al (2011) L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer. Mol Cancer 10:127CrossRefGoogle Scholar
  23. 23.
    Tamura M et al (2005) Prognostic significance of dysadherin expression in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 130(3):740–745CrossRefGoogle Scholar
  24. 24.
    Maeda J et al (2008) Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy. Br J Cancer 98(3):596–603CrossRefGoogle Scholar
  25. 25.
    Richardson F et al (2012) The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy. Anticancer Res 32(2):537–552Google Scholar
  26. 26.
    Chikaishi Y, Uramoto H, Tanaka F (2011) The EMT status in the primary tumor does not predict postoperative recurrence or disease-free survival in lung adenocarcinoma. Anticancer Res 31(12):4451–4456Google Scholar
  27. 27.
    Soltermann A et al (2008) Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res 14(22):7430–7437CrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2017

Authors and Affiliations

  1. 1.Department of Thoracic surgery the First People’s Hospital of YanchengYanchengChina
  2. 2.Department of Thoracic surgerythe Affiliated Hospital of Nantong UniversityNantongChina
  3. 3.Department of PathologyThe Affiliated Hospital of Nantong UniversityNantongChina

Personalised recommendations